Brian Lannutti

Brian Lannutti

Company: Velosbio

Job title: Senior Vice President - Research & Development

Seminars:

Live Discussion & Question Time 2:30 pm

Read more

day: Track A - Day 1 PM

ROR1 Targeting with the Antibody Drug-Conjugate VLS-101 in Aggressive Non-Hodgkins Lymphoma 1:30 pm

ROR1 is an onco-embryonic cell surface receptor with expression in various cancers The novel antibody-drug conjugate VLS-101 demonstrates promising in vivo activity in preclinical Lynphoma models Confirm ROR1 as a target and demonstrate the therapeutic potential of using an ADC directed toward ROR1 for the treatment of hematological cancersRead more

day: Track A - Day 1 PM

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.